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OBJECTIVE — New clinical practice recommendations include A1C as an alternative to
fasting glucose as a diagnostic test for identifying pre-diabetes. The impact of these new recom-
mendations on the diagnosis of pre-diabetes is unknown.
RESEARCHDESIGNANDMETHODS — DatafromtheNationalHealthandNutrition
Examination Survey 1999–2006 (n  7,029) were analyzed to determine the percentage and
number of U.S. adults without diabetes classiﬁed as having pre-diabetes by the elevated A1C
(5.7–6.4%)andbytheimpairedfastingglucose(IFG)(fastingglucose100–125mg/dl)criterion
separately. Test characteristics (sensitivity, speciﬁcity, and positive and negative predictive val-
ues) using IFG as the reference standard were calculated.
RESULTS — The prevalence of pre-diabetes among U.S. adults was 12.6% by the A1C crite-
rionand28.2%bythefastingglucosecriterion.Only7.7%ofU.S.adults,reﬂecting61and27%
of those with pre-diabetes by A1C and fasting glucose, respectively, had pre-diabetes according
to both deﬁnitions. A1C used alone would reclassify 37.6 million Americans with IFG to not
having pre-diabetes and 8.9 million without IFG to having pre-diabetes (46.5 million reclassi-
ﬁed).UsingIFGasthereferencestandard,pre-diabetesbytheA1Ccriterionhas27%sensitivity,
93% speciﬁcity, 61% positive predictive value, and 77% negative predictive value.
CONCLUSIONS — Using A1C as the pre-diabetes criterion would reclassify the pre-
diabetes diagnosis of nearly 50 million Americans. It is imperative that clinicians and health
systems understand the differences and similarities in using A1C or IFG in diagnosis of
pre-diabetes.
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D
iabetes, a condition associated with
high morbidity and mortality, has
reached epidemic status among
Americans (1). At present, 24 million
Americans have diabetes with indirect
and direct costs exceeding 174 billion
dollars annually (1,2). The high burden
and prognostic implications of diabetes
have led to increasing attempts to prevent
its development. Interventions for indi-
viduals and populations at high risk for
diabetes or with pre-diabetes are a major
focus for these prevention efforts (3).
Untilrecently,clinicalpracticeguide-
lines have deﬁned pre-diabetes as either
impaired fasting glucose (IFG) (fasting
plasma glucose [FPG] of 100–125 mg/dl)
or impaired glucose tolerance (IGT) (glu-
cose of 140–199 mg/dl on a 2-h oral glu-
cose tolerance test [OGTT]). Using these
deﬁnitions, 57 million Americans have
pre-diabetes (1). In clinical practice, FPG
is a more commonly used test, compared
with an OGTT, because of its logistical
advantages (4). However, IFG still re-
quires individuals to fast for at least 8 h
before testing.
The American Diabetes Association
(ADA) recently updated its screening rec-
ommendation for pre-diabetes to include
A1C, a nonfasting test, as another diag-
nostic testing option (5). Speciﬁc to pre-
diabetes, these recommendations state
that A1C from 5.7 to 6.4% identiﬁes in-
dividualsathighriskfordiabetesandthat
the label of pre-diabetes can be applied
(5). The revised recommendations imply
that the practical advantages of A1C over
FPGandOGTTwillmakescreeningmore
widespread and help clinicians identify
and intervene in this high-risk popula-
tion. The guidelines do not comment on
whether clinicians should use each test in
isolation or in combination, but logistical
advantages may make A1C a clinician’s
preferred test.
In this study, we used data from the
National Health and Nutrition Examina-
tion Survey (NHANES) 1999–2006 to
evaluate the impact of this new recom-
mendation on the proportion of Ameri-
cansinthegeneralpopulationwhowould
be classiﬁed as having pre-diabetes. Spe-
ciﬁcally,weexaminedtheconcordancein
the number of U.S. adults identiﬁed as
having pre-diabetes via FPG and A1C. In
addition, we determined differences and
similarities among the populations iden-
tiﬁed as having pre-diabetes by the A1C
criterion and also by the IFG screening
criterion.
RESEARCH DESIGN AND
METHODS— NHANES 1999–2000,
2001–2002, 2003–2004, and 2005–
2006 are serial cross-sectional surveys in-
cluding nationally representative samples
of the noninstitutionalized civilian U.S.
populationidentiﬁedthroughastratiﬁed,
multistage probability sampling design.
Methods for pooling these datasets are
published on the NHANES website (6).
NHANES 1999–2006 included 7,975
adults, aged 20 years, who attended the
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9–24 h at the time of their blood collec-
tion. Participants missing FPG or A1C
measurements (n  37) with a prior self-
reported diagnosis of diabetes (n  537)
andthosemeetingthecriteriafordiabetes
(FPG 126 mg/dl or A1C 6.5%) were
excluded(n372)fromthecurrentanal-
yses. After these exclusions, the current
analyses were based on data from 7,029
participants without diabetes.
NHANES data were collected through
questionnaires, a physical examination,
and blood collection. Details of the phle-
botomy process in NHANES 1999–2006
are provided elsewhere (6). Of particular
relevance to the current report, serum
glucose was measured using a modiﬁed
hexokinase enzymatic method, and A1C
was measured using a high-performance
liquid chromatography system by the Di-
abetes Diagnostic Laboratory at the Uni-
versity of Missouri–Columbia and by the
Fairview Medical Center Laboratory at
the University of Minnesota for 2005–
2006. A1C and glucose values were reca-
librated for NHANES 2005–2006 to
account for the differences in the assays
used among laboratories (7,8). Both as-
says have been validated and are Diabetes
Complications and Control Trial–aligned
(9). The coefﬁcient of variation was 3%
in each 2-year period for glucose and
2% for A1C.
In 2005–2006, a subset of 1,680 par-
ticipants completed an OGTT after an
overnight fast of 9–24 h. Of these partic-
ipants, the current analysis was con-
ductedamong1,382participantswithout
diabetes(i.e.,noself-report,A1C6.5%,
FPG 126 mg/dl, and OGTT 200 mg/
dl). After the initial venipuncture, partic-
ipants were asked to drink a calibrated
dose, 75 g of glucose, and had a second
venipuncture2h( 15 min) later.
Statistical analysis
Participants were categorized into one of
four mutually exclusive groups by the
presence or absence of pre-diabetes ac-
cording to IFG and A1C criteria. Charac-
teristics of the study population were
calculatedforeachofthesefourcategories
as mean  SE, median (25th, 75th per-
centiles), or percentages, as appropriate.
The prevalence of pre-diabetes was then
calculated for IFG and various cut points
of A1C. The sensitivity, speciﬁcity, and
positiveandnegativepredictivevaluesfor
havingpre-diabetesbyIFGwerethencal-
culated for each A1C level. In addition,
thenumberofU.S.adultswithdiscordant
pre-diabetes results based on IFG and
A1C values was determined. Two sensi-
tivity analyses were conducted. First, the
testcharacteristicsofpre-diabetesbyA1C
versus IFG deﬁned as FPG levels of 110–
125 mg/dl, the previous fasting glucose
range for deﬁning pre-diabetes, were de-
termined.Second,usingthesubsetofpar-
ticipants with OGTT results, the
sensitivity, speciﬁcity, and positive and
negative predictive values were deter-
mined for pre-diabetes by IFG and A1C,
separately, and for the presence of either
or both of these test results using IGT as
the reference standard. All analyses were
weightedtorepresenttheU.S.population
and conducted using SUDAAN (version
9; Research Triangle Institute, Research
Triangle Park, NC) to account for the
complex survey design of NHANES.
NHANES sampling weights were ad-
justed to account for missing values.
Adjustment of the sampling weights cor-
rectsfordifferencesinmissingdataacross
age, sex, and race/ethnicity strata but as-
sumes that data within strata are missing,
randomly (10).
RESULTS— Participants with pre-
diabetes by A1C but not by IFG were
more likely to be women, non-Hispanic
blacks, and hypertensive and to have hy-
percholesterolemia, chronic kidney dis-
ease, microalbuminuria, elevated
C-reactive protein, and lower triglycer-
ides than those with pre-diabetes by IFG
but normal A1C (Table 1). Overall, par-
ticipants with pre-diabetes by both crite-
ria had higher levels of the cardiovascular
risk factors investigated.
Table 2 depicts how various A1C cut
points affect the potential distribution of
U.S. adults categorized as having pre-
diabetes by the A1C and/or IFG criteria.
The recommended pre-diabetes A1C
range between 5.7 and 6.4% provides the
highest agreement with IFG. Nonethe-
less,theoverlapislow;amongU.S.adults
without diabetes, 7.7% have pre-diabetes
according to both the IFG and A1C crite-
ria, whereas 4.9% have pre-diabetes by
the A1C but not the IFG criterion and
20.5% by the IFG but not the A1C
criterion (Fig. 1).
The prevalence of pre-diabetes by the
IFGcriterionwas28.2%.UsingIFGasthe
reference standard for pre-diabetes, A1C
levels between 5.7% and 6.4% would re-
classify 37.6 million Americans with IFG
asnothavingpre-diabetesand8.9million
without IFG as having pre-diabetes for a
totalof46.5millionreclassiﬁed(Table3).
AthigherA1Ccutpointsfordeﬁningpre-
diabetes,thenumberofU.S.adultsreclas-
siﬁed as having pre-diabetes by A1C but
not IFG is lower. This modiﬁcation de-
creases the sensitivity and negative pre-
dictive value of diagnosing pre-diabetes
but at the same time increases the speci-
ﬁcity and positive predictive value. The
total number of U.S. adults reclassiﬁed,
using IFG as the reference standard for
pre-diabetes, is lowest at an A1C level of
5.7–6.4%.
Sensitivity analyses
When a more restrictive IFG deﬁnition
(i.e., FPG of 110–125 mg/dl) is applied,
the prevalence of pre-diabetes decreases
from 28.2–7.7%. Of the 20.5% of U.S.
adults (n  37.6 million) with pre-
diabetes by IFG but not A1C, 79.0% (n 
29.8 million) have FPG between 100 and
109 mg/dl. Overall, 9.1% of U.S. adults
have pre-diabetes by A1C but a FPG
110 mg/dl, 4.9% have A1C in the nor-
mal range but FPG of 110–125 mg/dl,
and 3.4% have both pre-diabetes level
A1CandFPGof110–125mg/dl.Thetest
characteristicsforpre-diabetesdeﬁnedby
A1C using FPG levels of 110–125 mg/dl
rather than 100–125 mg/dl as the refer-
ence criterion, produces a lower sensitiv-
ity (45%) and speciﬁcity (90%). Further,
because the prevalence of pre-diabetes is
lower,asexpected,thepositivepredictive
value(27%)islowerandthenegativepre-
dictive value (95%) is higher.
The prevalence of pre-diabetes by
IGT was 16.5%, whereas 5.7 and 11.6%
of U.S. adults have pre-diabetes via IGT
despite normal FPG and A1C, respec-
tively. However, using IGT alone would
classify 24.3 and 9.4% of U.S. adults as
not having pre-diabetes despite pre-
diabetes by IFG and A1C, respectively.
With IGT as the reference standard, the
sensitivity, speciﬁcity, and positive and
negative predictive values for pre-
diabetes were 30, 89, 33, and 87% by
A1C;59,79,34,and91%byIFG;22,95,
43,and87%byA1CandIFG;and66,73,
31, and 92% by A1C or IFG, respectively.
CONCLUSIONS — Data from the
current study indicate that the 2010 ADA
recommendations for inclusion of A1C as
an acceptable pre-diabetes diagnostic cri-
terion will have a substantial impact on
the number of U.S. adults identiﬁed as
havingpre-diabeteswiththeclassiﬁcation
being different for nearly 50 million
Americans. If providers use A1C alone,
they will classify 8.9 million people who
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fasting glucose as having pre-diabetes.
However, they will also reclassify 37.6
million people as not having pre-diabetes
by A1C who would have been labeled as
having pre-diabetes by the IFG criteria.
This discordance is in contrast to a rela-
tively good agreement between A1C and
fasting glucose when applied to the diag-
nosis of diabetes (11).
The inclusion of A1C is designed to
increase the feasibility and dissemination
ofdiabetesscreeningbecauseiteliminates
the need for fasting before testing. This
practical advantage is likely to be well re-
ceivedbyprimarycareprovidersworking
in environments with increasing con-
straints. Because A1C, FPG, and OGTT
are all considered acceptable diagnostic
tests for pre-diabetes by the ADA, there
may be a strong shift toward using A1C
alone to identify patients with pre-
diabetes and diabetes. Recent data dem-
onstrating A1C as an independent
predictor of incident cardiovascular dis-
easeanddeathinadditiontodiabeteswill
only reinforce this shift (12). The current
data suggest that further discussion is
neededbecauseusingA1Calonewilllead
toareclassiﬁcationasnormalofmanypa-
tients who previously (i.e., using IFG)
were considered to have pre-diabetes.
This reclassiﬁed group includes a large
number of individuals (n  8 million)
with fasting glucose in the range of 110–
125mg/dl.Fastingglucoseinthisrangeis
associated with a substantially higher risk
for diabetes incidence (5–7 times greater
thanthatwithfastingglucoseof100–109
mg/dl)(13).Whereascombineduseofei-
Table 2—Distribution of U.S. adults without diagnosed diabetes by the cross-classiﬁcation of
A1C and fasting glucose, using different A1C cut points
A1C cut point
 A1C cut point  A1C cut point
FPG 100
mg/dl
FPG 100
mg/dl
FPG 100
mg/dl
FPG 100
mg/dl
5.3% 39.8  1.3 7.3  0.5 32.0  0.9 20.9  0.8
5.4% 48.2  1.3 10.3  0.6 23.6  0.9 17.9  0.7
5.5% 57.8  1.3 13.8  0.7 14.0  0.7 14.4  0.6
5.6% 63.2  1.2 17.5  0.8 8.6  0.5 10.8  0.5
5.7% 66.9  1.1 20.5  0.9 4.9  0.3 7.7  0.4
5.8% 69.2  1.1 23.0  1.0 2.5  0.2 5.3  0.4
5.9% 70.2  1.1 24.6  1.0 1.6  0.2 3.7  0.3
6.0% 71.1  1.1 25.8  1.1 0.7  0.1 2.5  0.2
6.1% 71.4  1.1 26.7  1.1 0.4  0.1 1.6  0.2
6.2% 71.6  1.1 27.3  1.1 0.2  0.1 0.9  0.1
6.3% 71.7  1.1 27.8  1.1 0.1  0.1 0.4  0.1
6.4% 71.8  1.1 28.1  1.1 0  0 0.1  0.004
Data are prevalence estimates  SE.
Table 1—Characteristics of NHANES 1999–2006 study participants by A1C and fasting glucose
A1C 5.7% A1C 5.7%
FPG 100 mg/dl FPG 100 mg/dl FPG 100 mg/dl FPG 100 mg/dl
n 4,439 1,430 446 714
Age (years) 40.8  0.4 49.1  0.6 54.0  0.9 58.1  0.6
Women (%) 57.8 36.0 54.2 51.3
Race/ethnicity
Non-Hispanic white (%) 76.2 80.8 62.5 71.7
Non-Hispanic black (%) 11.2 5.6 25.5 15.2
Hispanic (%) 7.5 8.3 8.2 7.0
Current smoker (%) 25.8 22.2 27.1 20.7
Systolic blood pressure (mmHg) 118.3  0.4 125.9  0.6 129.9  1.1 130.7  0.8
Diastolic blood pressure (mmHg) 70.5  0.3 72.5  0.4 72.2  0.7 71.8  0.7
Hypertension (%) 18.1 34.2 40.8 53.4
BMI (kg/m
2) 26.8  0.1 29.4  0.3 29.9  0.4 31.4  0.4
Waist circumference (cm) 92.1  0.3 101.0  0.6 101.2  1.0 105.4  0.7
Total cholesterol (mg/dl) 198.0  0.9 205.1  1.4 211.7  2.5 207.6  2.1
HDL cholesterol (mg/dl) 55.1  0.3 50.0  0.6 51.1  0.9 49.5  0.7
Triglycerides (mg/dl) 102 (73–149) 134 (91–192) 129 (90–188) 136 (101–195)
eGFR 60 ml/min per 1.73m
2 (%) 6.1 8.7 12.3 15.5
Microalbuminuria (%) 5.6 8.3 13.1 13.3
Hemoglobin (g/dl) 14.4  0.1 15.0  0.1 14.3  0.1 14.6  0.1
Serum albumin (g/dl) 4.30  0.01 4.32  0.01 4.17  0.03 4.18  0.02
Ferritin (ng/ml) 56 (28–111) 104 (51–193) 81 (32–159) 93 (45–173)
Aspartate aminotransferase (units/l) 24.2  0.3 26.5  0.5 27.1  1.7 25.6  0.4
Alanine aminotransferase (units/l) 24.3  0.3 30.3  1.8 28.7  2.1 27.9  0.8
C-reactive protein 2 mg/l (%) 45.4 55.2 65.0 69.5
Fasting plasma glucose (mg/dl) 90.2  0.2 106.1  0.2 93.3  0.3 109.6  0.4
A1C (%) 5.2 (5.0–5.3) 5.3 (5.1–5.5) 5.8 (5.7–5.9) 5.9 (5.8–6.0)
Data are  SE, %, or median (25th–75th percentiles). eGFR, estimated glomerular ﬁltration rate.
A1C screening for pre-diabetes
2192 DIABETES CARE, VOLUME 33, NUMBER 10, OCTOBER 2010 care.diabetesjournals.orgther IFG or A1C as the criteria of pre-
diabetes would be more sensitive, it
would eliminate the practical advantages
of using A1C alone.
Itisimportanttorecognizethateither
criterion (fasting glucose or A1C) is a di-
agnostic test, not a traditional screening
test in that it is not compared with a true
criterion standard. Astute clinicians may
recognize the shortcomings of each test;
however, many providers will probably
choose only one or the other for use in
practice. The clinical guidelines do not
comment on the need for follow-up test-
ing for pre-diabetes. This situation in-
creasesthelikelihoodofhigherdegreesof
variation in screening practices with a
possibility of more confusion among pro-
vidersandpatients.Educationalinterven-
tions may need to be developed to help
primary care providers and patients un-
derstand the advantages and shortcom-
ings of each test used alone or in
combination.
Pre-diabetes is a label developed to
identify those at highest risk for inci-
dent diabetes in the near future. Data
from observational studies suggest that
25–40% of individuals with pre-
diabetes will develop diabetes over the
next 3–8 years (14–16). Guidelines
suggest targeting individuals identiﬁed
as having pre-diabetes for early inter-
ventions. Currently, the most effective
intervention for the prevention or delay
ofdiabetesisintensivelifestylebehavior
change with metformin therapy a less
potent alternative (14). Whereas inten-
sive lifestyle interventions are recom-
mended for individuals identiﬁed via
IFG, A1C, or IGT, current guidelines rec-
ommend that metformin be reserved for
those with both combined IFG and IGT
plus other risk factors such as A1C 6%,
hypertension, low HDL cholesterol, ele-
vated triglycerides, or a family history of
diabetes in a ﬁrst-degree relative who are
obese and aged 60 years (5). This rec-
ommendation has led some investigators
to call for follow-up IGT testing in all in-
dividuals identiﬁed as having pre-
diabetes based on their fasting glucose
(17).Thisisinpartduetotheobservation
that the odds for incident diabetes are
fourfold higher among individuals with
both IFG and IGT than either alone (odds
ratio 39.5 vs. 10.0 and 10.9, respectively)
(18). With the use of A1C as a legitimate
alternative diagnostic criterion for pre-
diabetes, the need for a follow-up OGTT
before prescribing metformin may be-
comeapointofcontention.IfanOGTTis
not performed, combined criteria of A1C
with follow-up IFG testing could be used
because this group would also be very
highrisk,andthedatacouldbecombined
with other metabolic abnormalities using
one of the established diabetes risk calcu-
lators to generate a more precise risk esti-
mate (19,20). Which criterion is more
accurate and clinically relevant for pre-
dicting diabetes and tailoring interven-
tions will need to be examined in future
prospective studies.
The low concordance among A1C-,
IFG-, and IGT-based diagnosis of pre-
diabetes highlights the multifactorial
pathophysiology of glucose dysfunction.
IFGispredominatelyadysfunctioninhe-
patic insulin resistance, whereas IGT is
dominated by muscle insulin resistance
(21).Eachisalsoassociatedwithdysfunc-
tional insulin secretion but with different
patterns (21). In contrast to the daily glu-
cose snapshot offered by IFG and IGT,
A1C represents chronic exposure (over
2–3 months) to basal and postprandial
hyperglycemiaandreﬂectsacombination
of these mechanisms (22). Together, the
different mechanisms underlying each
testhelpexplainthediscordantdiagnoses
of pre-diabetes using IFG, A1C, and
OGTT. As diabetes itself develops, each
underlying mechanism plays a role,
Figure 1—Overlap of pre-diabetes by IFG and A1C among U.S. adults without diabetes. %,
percentage of U.S. adults. IFG, FPG of 100–125 mg/dl; M, million.
Table3—Sensitivity,speciﬁcity,positivepredictivevalue,negativepredictivevalue,andnum-
ber reclassiﬁed according to different A1C cut points
A1C cut
point
Test characteristics (%)
Number reclassiﬁed
(millions)
Sensitivity Speciﬁcity
Positive
predictive
value
Negative
predictive
value IFG No IFG
Total
reclassiﬁed
n 51.7 131.4
5.3% 74 55 40 84 13.4 58.6 72.0
5.4% 63 67 43 82 18.9 43.2 62.1
5.5% 51 81 51 81 25.3 25.6 50.9
5.6% 38 88 56 78 32.0 15.8 47.8
5.7% 27 93 61 77 37.6 8.9 46.5
5.8% 19 96 68 75 42.0 4.6 46.6
5.9% 13 98 70 74 45.0 2.9 47.9
6.0% 9 99 77 73 47.2 1.3 48.5
6.1% 6 99 82 73 48.8 0.6 49.4
6.2% 3 100 82 72 49.9 0.3 50.2
6.3% 1 100 87 72 51.0 0.1 51.1
6.4% 0 100 98 72 51.5 0.0 51.5
For test characteristics, values higher than the A1C cut point are considered positive test results, and fasting
plasma glucose of 100–125 mg/dl is the reference standard for pre-diabetes. In calculating the number
reclassiﬁed, NHANES sampling weights were adjusted to account for missing values. Speciﬁcally, sampling
weights were calibrated based on the proportion of NHANES 1999–2004 participants missing data by
age-group (40, 40–59, 60–74, and 75 years), sex, and race/ethnicity. Adjusting the sampling weights
correct for differences in missing data across age, sex, and race/ethnicity strata but assumes that data within
strata are missing randomly (10).
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concordance between A1C and IFG in di-
abetes (11). Nevertheless, clinicians need
to be aware that each test will classify as
normal a substantial proportion of those
found to be pre-diabetic by one of the
other tests.
The current study needs to be inter-
pretedinthecontextofcertainpotential
limitations. Most notably, each test
(FPG, A1C, and OGTT) was only per-
formed once in NHANES 1999–2006,
and the test results may change over
time. Even though the coefﬁcient of
variation for A1C is quite small, the
clustering of pre-diabetes around 5.8%
suggests that small differences could
have a disproportionate impact on clas-
siﬁcation of pre-diabetes. However, un-
published sensitivity analyses (and
Table 2) that vary the pre-diabetes A1C
criteria to 5.6% showed insigniﬁcant
differences. In addition, hemolytic ane-
miasareknowntoartiﬁciallylowerA1C
levels although this concern is minimal,
considering the relative rarity of these
conditionscomparedwithpre-diabetes.
Despite these limitations, the current
study has many strengths. Most nota-
bly, NHANES 1999–2006 uses a com-
plex stratiﬁed sampling design to
recruit participants, which allows esti-
mates to be made for the U.S. popula-
tion. In addition, NHANES 1999–2006
includes a broad range of demographic,
medical,andbiochemicaldatacollected
by trained staff, following a standard-
ized protocol.
In summary, the revised 2010 ADA
Standards of Medical Care in Diabetes in-
cludes three options for identifying pa-
tients at high risk for diabetes: FPG, A1C,
and OGTT. Previously, IFG has been far
preferred over IGT owing to its logistical
advantages. Because A1C has signiﬁcant
practical advantages over IFG, it is likely
to become the preferred test among pri-
mary care providers for diagnosing pre-
diabetes. The clinical impact of this
change is not yet known, but the current
analysis suggests that it will substantially
alter the population identiﬁed as having
pre-diabetes with tens of millions of
Americans who would have been consid-
ered to have pre-diabetes previously be-
ing classiﬁed as not having pre-diabetes.
This subgroup of individuals includes a
substantial number with fasting glucose
levels of 110–125 mg/dl and a burden of
cardiovascular risk factors similar to that
of their counterparts with pre-diabetes by
A1C and IFG. The impact of not identify-
ing these individuals is unclear. Policy
makers and clinicians will need to con-
sider the tradeoffs between performing
both FPG and A1C testing alone or in
combination.
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